Cover Image
市場調查報告書

全身性乾癬治療藥的全球市場:2016年∼2020年

Global Systemic Psoriasis Therapeutics Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 363474
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
全身性乾癬治療藥的全球市場:2016年∼2020年 Global Systemic Psoriasis Therapeutics Market 2016-2020
出版日期: 2016年07月12日 內容資訊: 英文 88 Pages
簡介

全球全身性乾癬治療藥市場在2016年∼2020年間預測將以年複合成長率 (CAGR) 9.41%的速度成長。

本報告提供全球全身性乾癬治療藥市場相關調查分析,提供您市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

第1章 摘要整理

第2章 調查範圍

  • 市場概要
  • 前提條件
  • 主要供應商產品

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 簡介

  • 主要市場焦點

第5章 乾癬:疾病概要

  • 盛行率
  • 乾癬的經濟負擔

第6章 全身性乾癬治療藥的開發平台分析

  • 開發平台候補藥所標的的新機制

第7章 市場形勢

  • 市場概要
  • 波特的五力分析

第8章 全身性乾癬治療藥的全球市場:各分子類型

  • 全球生技藥品市場
  • 小分子

第9章 全身性乾癬治療藥的全球市場:各作用機制

  • TNF抑制劑
  • PDE4抑制劑
  • ILBroker
  • 其他

第10章 全身性乾癬治療藥的全球市場:疾病的嚴重度別

  • 輕度
  • 中度
  • 重度

第11章 全身性乾癬治療藥的全球市場:各給藥途徑

  • 口服
  • 非口服

第12章 全身性乾癬治療藥的全球市場:各地區

  • 南北美洲
  • 美國
  • 歐洲·中東·非洲
  • 亞太地區

第13章 全身性乾癬治療藥的全球市場:推動因素

第14章 推動因素的影響

第15章 全身性乾癬治療藥的全球市場:課題

第16章 推動因素與課題的影響

第17章 全身性乾癬治療藥的全球市場:趨勢

第18章 業者情勢

  • 競爭模式
  • 今後的供應商
  • 主要消息
  • AbbVie
  • Johnson & Johnson
  • Celgene
  • Amgen
  • Pfizer
  • 其他卓越供應商

第19章 附錄

第20章 關於Technavio

目錄
Product Code: IRTNTR9772

About the Systemic Psoriasis Therapeutics Market

Psoriasis is a commonly diagnosed immune-mediated disease of the skin. In psoriasis, the skin grows fast and causes a build-up of red, thick white, or silvery patches. It modifies the normal cell cycle of the skin such that new cells move to the surface of the skin quickly to form patches called plaques. These plaques are commonly found on the knees, elbows, scalp, hand and feet. The condition mostly occurs among adults (18 years-35 years), but can also be seen in adolescents (12 years-18 years) and children (under 10 years).

Psoriasis is more prevalent among Caucasians compared to African-Americans. According to a World Health Organization (WHO) document of 2015, the global prevalence of psoriasis is approximately 2%-3%. However, it is approximately 4.6% in developed countries. In addition, the risk of an individual getting diagnosed with psoriasis is 41% if both parents have psoriasis, 14% in case one parent is affected, and 6% if a sibling has psoriasis.

Technavio's analysts forecast the global systemic psoriasis therapeutics market to grow at a CAGR of 9.41% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global systemic psoriasis therapeutics market for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the from the sales of branded, generic, and off-label drugs used to treat psoriasis. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Systemic Psoriasis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • Johnson & Johnson
  • Celgene
  • Amgen
  • Pfizer

Other Prominent Vendors

  • AbGenomics
  • Almirall
  • Anacor Pharmaceuticals
  • ApoPharma
  • Astellas Pharma
  • AstraZeneca
  • Aurinia Pharmaceuticals
  • Biocon
  • Biogen Idec
  • Biotest
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Can-Fite BioPharma
  • Cellceutix Corporation
  • Coherus Biosciences
  • Creabilis
  • Crescendo Biologics
  • Delenex Therapeutics
  • Dermira
  • Eli Lilly
  • F. Hoffmann-La Roche
  • Forward Pharma
  • G & W Laboratories
  • GlaxoSmithKline
  • Idera Pharmaceuticals
  • Incyte
  • Kadmon
  • kinetabio
  • KPI Therapeutics
  • Kyowa Hakko Kirin
  • LEO Pharma
  • Maruho
  • Merck
  • Mitsubishi Tanabe Pharma
  • Moleculin
  • MorphoSys
  • Novartis
  • Prism Pharma
  • Promius Pharma
  • Prothena Biosciences
  • Provectus Biopharmaceuticals
  • Sandoz
  • Sun Pharmaceuticals
  • Takeda Pharmaceuticals
  • Taro Pharmaceuticals
  • TFS
  • UCB
  • Valeant Pharmaceuticals
  • VBL Therapeutics
  • XenoPort
  • Ziarco Pharma

Market driver

  • Dominance of market by biologics
  • For a full, detailed list, view our report

Market challenge

  • Physician's reluctance to prescribe biosimilars
  • For a full, detailed list, view our report

Market trend

  • Advent of biologics with novel MOA and cell-based strategies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Assumptions
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Psoriasis: Condition overview

  • Prevalence
  • Economic burden of psoriasis

PART 06: Pipeline analysis

  • Novel mechanisms targeted by pipeline candidates

PART 07: Market landscape

  • Market overview
  • Five forces analysis

PART 08: Market segmentation by type of molecule

  • Global biologics market
  • Small molecules

PART 09: Market segmentation by mechanism of action

  • TNF inhibitors
  • PDE4 inhibitors
  • IL blockers
  • Others

PART 10: Market segmentation by severity of disease

  • Mild psoriasis
  • Moderate psoriasis
  • Severe psoriasis

PART 11: Market segmentation by ROA

  • Oral
  • Parenteral

PART 12: Geographical segmentation

  • Systemic psoriasis therapeutics market in Americas
  • Systemic psoriasis therapeutics market in US
  • Systemic psoriasis therapeutics market in EMEA
  • Systemic psoriasis therapeutics market in APAC

PART 13: Market drivers

  • Dominance of market by biologics
  • Increase in psoriatic patient pool due to new diagnostic procedures
  • Recurrence of psoriasis
  • Expected approval of late-stage pipeline molecules

PART 14: Impact of drivers

PART 15: Market challenges

  • Physician's reluctance to prescribe biosimilars
  • Innovative blue LED device and magnetic therapy as potential therapeutics substitutes
  • Unknown disease etiology
  • Use of CAM and topical drugs to treat psoriasis

PART 16: Impact of drivers and challenges

PART 17: Market trends

  • Advent of biologics with novel MOA and cell-based strategies
  • Emergence of next-generation systemic psoriatic therapies
  • Preference for combination therapies
  • Popularity of off-label systemic medications

PART 18: Vendor landscape

  • Competitive scenario
  • Upcoming vendors
  • Key news
  • AbbVie
  • Johnson & Johnson
  • Celgene
  • Amgen
  • Pfizer
  • Other prominent vendors

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Economic burden of psoriasis
  • Exhibit 03: Annual treatment costs of psoriasis 2014 ($)
  • Exhibit 04: Global systemic psoriasis therapeutics market: Pipeline portfolio
  • Exhibit 05: Pipeline share of molecules in different stages of development 2015
  • Exhibit 06: Novel targets of pipeline candidates
  • Exhibit 07: Share of novel pipeline molecules based on their MOA 2015
  • Exhibit 08: Approvals and patent expiries of top selling biologics
  • Exhibit 09: Global systemic psoriasis therapeutics market 2015-2020 ($ billions)
  • Exhibit 10: Global systemic psoriasis therapeutics market snapshot: Developed and emerging markets 2015
  • Exhibit 11: A few patient assistance programs offered by various companies
  • Impact of drivers and challenges on the market
  • Exhibit 12: Impact of key customer segments on market 2015
  • Exhibit 13: Opportunities faced by psoriasis industry today
  • Exhibit 14: Five forces analysis
  • Exhibit 15: Global systemic psoriasis therapeutics market: Segmentation by type of molecule (2015-2020)
  • Exhibit 16: Global systemic psoriasis therapeutics market: Segmentation by type of molecule 2015
  • Exhibit 17: Competitive assessment of marketed and late-stage pipeline molecules
  • Exhibit 18: Global biologics market 2015-2020 ($ billions)
  • Exhibit 19: Opportunity analysis of global systemic psoriasis therapeutics market by type of molecule
  • Exhibit 20: Impact of biologics on various sectors
  • Exhibit 21: Global small molecules market 2015-2020 ($ millions)
  • Exhibit 22: Average percentage of patients receiving TNF inhibitors 2010 and 2015
  • Exhibit 23: Global systemic psoriasis therapeutics market segmentation by MOA 2015
  • Exhibit 24: Global systemic psoriasis therapeutics market segmentation by MOA 2020
  • Exhibit 25: Global systemic psoriasis therapeutics market segmentation by severity of disease 2015
  • Exhibit 26: Global systemic psoriasis therapeutics segmentation by ROA 2015
  • Exhibit 27: Global systemic psoriasis therapeutics market: Geographical outlook (2015-2020)
  • Exhibit 28: Global systemic psoriasis therapeutics market: Geography outlook 2015
  • Exhibit 29: Revenue/growth outlook in different countries/regions 2015
  • Exhibit 30: Systemic psoriasis therapeutics market in Americas 2015-2020 ($ billions)
  • Exhibit 31: Systemic psoriasis therapeutics market in America by country 2015
  • Exhibit 32: Systemic psoriasis therapeutics market in US 2015-2020 ($ billions)
  • Exhibit 33: Systemic psoriasis therapeutics market in EMEA 2015-2020 ($ billions)
  • Exhibit 34: Systemic psoriasis therapeutics market in APAC 2015-2020 ($ billions)
  • Exhibit 35: Global systemic psoriasis therapeutics market by geographical segmentation 2015
  • Exhibit 36: Global systemic psoriasis therapeutics market by geographical segmentation 2020
  • Exhibit 37: Global systemic psoriasis therapeutics market revenue by geography 2015-2020 ($ billions)
  • Exhibit 38: Biologicals approvals by US FDA
  • Exhibit 39: List of some pipeline molecules
  • Exhibit 40: Impact of drivers
  • Exhibit 41: Key reasons to prescribe biosimilars 2015
  • Exhibit 42: CAM and topical drugs for psoriasis
  • Exhibit 43: Usage of CAMs in US 2014
  • Exhibit 44: Impact of drivers and challenges
  • Exhibit 45: Psoriasis market: Impact assessment of top trends 2015
  • Exhibit 46: Market share of major vendors for global systemic psoriasis therapeutics market 2015
  • Exhibit 47: Competitive assessment of vendors
  • Exhibit 48: Key vendors: Geographical presence 2015
  • Exhibit 49: YoY sales comparison of top selling drugs 2013-2015 ($ billions)
  • Exhibit 50: Upcoming vendors
  • Exhibit 51: AbbVie: Product segmentation by revenue 2015
  • Exhibit 52: AbbVie: YoY revenue and growth rate of Humira 2013-2015 ($ billions)
  • Exhibit 53: AbbVie: YoY revenue and growth rate of Humira (in US) 2013-2015 ($ billions)
  • Exhibit 54: AbbVie: YoY revenue and growth rate of Humira (ROW) 2013-2015 ($ billions)
  • Exhibit 55: AbbVie: Metrics analysis
  • Exhibit 56: Johnson & Johnson: YoY growth rate and revenue of Remicade 2013-2015 ($ billions)
  • Exhibit 57: Johnson & Johnson: YoY growth rate and revenue of Remicade (in US) 2013-2015 ($ billions)
  • Exhibit 58: Johnson & Johnson: YoY growth rate and revenue of Remicade (ROW) 2013-2015 ($ billions)
  • Exhibit 59: Johnson & Johnson: YoY growth rate and revenue of Stelara 2013-2015 ($ billions)
  • Exhibit 60: Johnson & Johnson: YoY growth rate and revenue of Stelara (in US) 2013-2015 ($ millions)
  • Exhibit 61: Johnson & Johnson: YoY growth rate and revenue of Stelara (ROW) 2013-2015 ($ millions)
  • Exhibit 62: Johnson & Johnson: Metrics analysis
  • Exhibit 63: Celgene: YoY revenue comparison of Otezla 2014-2015 ($ millions)
  • Exhibit 64: Celgene: Metrics analysis
  • Exhibit 65: Amgen: YoY revenue and growth rate of Enbrel (in US and Canada) 2013-2015 ($ billions)
  • Exhibit 66: Amgen: YoY revenue and growth rate of Enbrel (in US) 2013-2015 ($ billions)
  • Exhibit 67: Amgen: YoY revenue and growth rate of Enbrel (in Canada) 2013-2015 ($ millions)
  • Exhibit 68: Amgen: Metrics analysis
  • Exhibit 69: Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2013-2015 ($ billions)
  • Exhibit 70: Pfizer: Metrics analysis
Back to Top